Comparison

Liraglutide vs. Survodutide

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Liraglutide

Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.

Survodutide

Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Liraglutide	Survodutide
Germany	Prescription	Unapproved
JP	—	Unapproved
United States	Prescription	Unapproved

Full entries

Frequently asked questions

What is the difference between Liraglutide and Survodutide?: Liraglutide is classified as "Metabolic", while Survodutide is classified as "Metabolic". Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). Survodutide: Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Liraglutide or Survodutide?: The highest available evidence level is "Human RCT" for Liraglutide and "Human RCT" for Survodutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Liraglutide and Survodutide in Germany and the United States?: Germany: Liraglutide — Prescription, Survodutide — Unapproved. United States: Liraglutide — Prescription, Survodutide — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Liraglutide

Survodutide

Germany

Prescription

Unapproved

—

Unapproved

United States

Prescription

Unapproved

Frequently asked questions

What is the difference between Liraglutide and Survodutide?

Liraglutide is classified as "Metabolic", while Survodutide is classified as "Metabolic". Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). Survodutide: Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Liraglutide or Survodutide?

The highest available evidence level is "Human RCT" for Liraglutide and "Human RCT" for Survodutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Liraglutide and Survodutide in Germany and the United States?

Germany: Liraglutide — Prescription, Survodutide — Unapproved. United States: Liraglutide — Prescription, Survodutide — Unapproved. These are factual summaries with source and review date on the individual pages.